The PNPLA3 Genetic Variant rs738409 Influences the Progression to Cirrhosis in HIV/Hepatitis C Virus Coinfected Patients by N&#250 et al.
RESEARCH ARTICLE
The PNPLA3 Genetic Variant rs738409
Influences the Progression to Cirrhosis in HIV/
Hepatitis C Virus Coinfected Patients
Rocı´o Nu´ñez-Torres1,2, Juan Macı´as1,2, Marı´a Mancebo1,2, Mario Frı´as3,4, Giovanni Dolci5,
Francisco Te´llez6, Dolores Merino7, Nicola´s Merchante1,2, Jesu´s Go´mez-Mateos1,2,
Giovanni Guaraldi5, Antonio Rivero-Jua´rez3,4, Juan A. Pineda1, Luis M. Real1,2*, on behalf
of HEPAVIR-esteatosis Study Group¶
1 Unit of Infectious Diseases and Microbiology, Valme University Hospital, Seville, Spain, 2 Instituto de
Biomedicina de Sevilla (IBIS), Seville, Spain, 3 Unit of Infectious Diseases, Reina Sofı´a University Hospital,
Co´rdoba, Spain, 4 Instituto Maimo´nides de Investigacio´n Biome´dica de Co´rdoba (IMIBC), University of
Co´rdoba, Co´rdoba, Spain, 5 Department of Medical and Surgical Science for Adults and Children, Clinic and
Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy, 6 Unit of Infectious Diseases,
La Lı´nea de la Concepcio´n Hospital, Ca´diz, Spain, 7 Unit of Infectious Diseases, Huelva University Hospital,
Huelva, Spain
¶ Complete membership of the author group can be found in the Acknowledgments.
* lmreal67b@gmail.com
Abstract
Contradictory data about the impact of the rs738409 steatosis-related polymorphism within
PNPLA3 gene on liver fibrosis progression in HIV/hepatitis C virus (HIV/HCV)-coinfected
patients have been reported. Our objective was to test whether this, and other polymor-
phisms previously related to fatty liver disease in HIV infection linked to SAMM50 or LPPR4
genes, influence liver fibrosis progression in HIV/HCV-coinfected individuals. Three hun-
dred and thirty two HIV/HCV-coinfected patients who consecutively attended four Spanish
university hospitals from November 2011 to July 2013 were included. A liver stiffness cut-off
of 14.6 kPa, as determined by transient elastography, was used to diagnose cirrhosis. Liver
stiffness progression was studied in 171 individuals who had two available LS determina-
tions without anti-HCV treatment between them. Moreover, 28 HIV/HCV-coinfected patients
who underwent liver transplant, as well as 19 non-cirrhotic coinfected individuals used as
controls, were included in an additional study. Only rs738409 was associated with cirrhosis:
45 (29.6%) of 152 G allele carriers versus 36 (20.0%) of 180 CC carriers showed cirrhosis
(multivariate p = 0.018; adjusted odds ratio = 1.98; 95% confidence interval = 1.12–3.50).
Also, 21 (30.4%) of 69 G allele carriers versus 16 (15.7%) of 102 CC patients showed signifi-
cant liver stiffness progression (adjusted p-value = 0.015; adjusted odds ratio = 2.89; 95%
confidence interval = 1.23–6.83). Finally, the proportion of rs738409 G allele carriers was
significantly higher in transplanted individuals than in controls (p = 0.044, odds ratio = 3.43;
95% confidence interval = 1.01–11.70). Our results strongly suggest that the rs738409 poly-
morphism is associated with liver fibrosis progression in HIV/HCV-coinfected patients.
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Introduction
Chronic infection with hepatitis C virus (HCV) may lead to advanced liver fibrosis and end-
stage liver disease. In HIV/HCV-coinfected individuals, liver fibrosis progression is accelerated
[1, 2]. Therefore, these individuals show a higher frequency of cirrhosis and end-stage liver dis-
ease. In spite of this, the rate of liver fibrosis progression is variable between patients. Several
risk factors for accelerated fibrosis have been previously identified in HIV/HCV-coinfected
patients [2–7].
As in other clinical conditions, host genetic factors could also influence the variability in
the progression of liver disease in HIV/HCV-coinfected patients. The identification of these
factors could help to understand the molecular basis of liver disease in HIV/HCV-coinfected
patients and may allow to identify those individuals at risk of developing advanced liver dis-
ease. Recently, several authors have analyzed whether the rs738409 genetic marker, located
within the patatin-like phospholipase domain-containing 3 (PNPLA3) gene, could be a risk
factor for liver fibrosis progression in HIV/HCV-coinfected patients with controversial results
[8–11]. This single nucleotide polymorphism (SNP) has been consistently associated with fatty
liver disease (FLD) in both HCV-uninfected and HCV-infected individuals [12, 13]. Similarly,
other SNPs that have been recently associated with FLD in the HIV-infected population [14]
could also have an impact on the faster liver fibrosis progression observed in the HIV/HCV-
coinfected population, but this has not been explored so far.
Because of the above reasons, the aims of this study were: i) to test whether the PNPLA3
rs738409 genetic marker is associated with liver damage progression in the HIV/HCV-coin-
fected population ii) to analyze if other SNPs, previously associated with FLD in HIV infected
population, such as SAMM50 rs738491 or LPPR4 rs12743824, could also be related to this
outcome.
Patients and Methods
Patients
This work comprises three different studies: two of them were cross-sectional (study 1 and
study 3) and the other one was a longitudinal retrospective assessment (study 2). The study
populations were as followed:
Study population 1. Those HIV-infected individuals with active HCV coinfection who con-
secutively attended the Infectious Diseases outpatient clinics in four university hospitals in
Spain from November 2011 to July 2013 were included. All patients underwent a liver stiffness
(LS) determination, as a noninvasive measurement of liver fibrosis, during a single visit previ-
ously scheduled as a routine follow-up visit. Data for this study were collected during the same
visit. In all patients, a whole blood sample was collected for routine laboratory and genetic
determinations.
From the entire study population 1, those patients who had two available LS determinations
separated at least by one year, without having received any treatment against HCV infection
between both determinations, were selected for the analysis of genetic associations with LS
progression (LSP). Clinical and demographic data corresponding to the date of the first LS
determination were obtained from the clinical records.
Study population 2. This population was composed of: i) Those HIV/HCV-coinfected
patients who underwent cadaveric donor liver transplant because of end-stage liver cirrhosis
related to HCV infection, and who donated genetic material at the time of transplantation,
according to an established procedure of the Centro Nazionale Trapianti (http://www.
trapianti.salute.gov.it/). All these individuals belonged to the Modena University Transplant
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cohort that started in 2003. ii) Those HIV/HCV-coinfected and non-cirrhotic individuals
from the same geographical area who had a known date of coinfection and who had DNA
samples available at the local bio-bank (Infectious Disease Clinic–Azienda policlinico Univer-
sitaria Modena, Italy).
All individuals were older than 18 and Caucasians. Pregnant women as well as those sub-
jects who showed family relationship with other selected patients were excluded from all of the
analyses.
Transient elastography examination
Liver stiffness with controlled attenuation parameter (CAP) measurements were performed by
an experienced operator at each participating center using a commercially available elastogra-
phy device (FibroScan 502, Echosens, Paris, France). Elastography examinations were con-
ducted as stated elsewhere [15, 16]. CAP is an estimate of the total ultrasonic attenuation and
it is expressed in dB/m. LS is expressed in kilopascals (kPa). According to previously reported
standards, examinations with 10 successful shots, an interquartile range for liver stiffness
lower than 30% of the median value and a success rate of at least 60%, were considered as reli-
able [16]. Cut-off values of 238 dB/m and 14.6 kPa were selected to define the presence of sig-
nificant steatosis and cirrhosis [15, 16], respectively.
Significant liver stiffness progression and liver stiffness progression rate
definitions
Significant LSP was defined as a 30% increment of LS in the second determination over the
first LS determination, being the difference between both LS determinations higher than 3
kPa. The LSP rate (LSPR) was calculated as the differences in kPa between both determinations
divided by the number of years elapsed between both determinations, and it was expressed in
kPa/year.
DNA isolation and polymorphism genotyping
DNA was extracted from frozen whole blood using the Quick Pure Blood DNA extraction Kit
(Macherey-Nagel, Du¨ren, Germany). The SNPs were genotyped using a custom Golden Gate
protocol (Illumina, San Diego, California USA).
Statistical analyses
The outcome variables were the presence of cirrhosis (study 1), the presence of significant LSP
(study 2) and the diagnosis of end-stage liver disease (study 3).
The online resource at the Institute for Human Genetics, Munich, Germany (http://ihg.gsf.
de) was used for testing comparison of genotypic frequencies between groups to determine dif-
ferent genetic models, p values, odds-ratios (OR), 95% confidence intervals (95% CI) as well
as the Hardy-Weinberg equilibrium. As a reference for genotypic and allelic frequencies of
rs738409 in the European Caucasian population, we used the data reported in the NCBI single
nucleotide polymorphisms database (http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?
rs=738409).
To compare the categorical variables in two different groups of individuals the Pearson chi-
square test was used. Quantitative variables among patient groups were compared by means of
the Student´s t-test (data normally distributed) or Mann-Whitney U test (data not normally
distributed). Logistic regression models were elaborated including variables with a univariate
p-value <0.2, as well as age and gender to obtain adjusted p and OR values and to detect
PNPLA3 and Cirrhosis in HIV/HCV Coinfection
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factors independently associated with the outcome variables. For the analysis of significant
LSP, the time between LS determinations was included in the models along with age, gender
and variables with an univariate p-value <0.2. All these analyses were carried out using the
SPSS software 22.0 (IBM Corporation, Somers, NY, USA).
The estimation of power to detect alleles associated with cirrhosis was performed by the
Episheet software available at http://members.aol.com/krothman.
Ethic statement
This study was performed according to the ethical guidelines of the Declaration of Helsinki.
The study was approved by the Ethics Committee of the Valme University Hospital and by the
Provincial Ethics Committee of Modena (pratica 183/14). Written consent was obtained from
all individuals before sampling.
Results
Study populations
Three hundred and thirty seven HIV-infected patients with active HCV coinfection were
selected. Five (1.5%) of them had not a reliable LS determination and were excluded. There-
fore, 332 individuals were included in the study population 1. Among them, a total of 124
(37.5%) individuals previously received treatment against HCV infection without sustained
virological response (SVR). The main characteristics of this population are depicted in Table 1.
To analyze LSP, one hundred and ninety-eight individuals who had two available LS deter-
minations separated at least by one year were selected. However, 27 (13.6%) of them received
anti-HCV treatment between LS determinations. Therefore, 171 (51.5%) out of 332 individuals
from the study population 1 were included in this subpopulation. Among them, 24 (14.7%)
had received anti-HCV treatment before the first LS determination without reaching SVR.
The median (quartile 1 –quartile 3) period between both LS measurements was 2.20 (1.30–
4.52) years. The median (quartile 1 –quartile 3) of LSPR was 0.06 (-0.50–1.10) kPa/year. The
characteristics of this subpopulation are depicted in Table 1.
Regarding the study population 2, twenty-eight liver-transplanted individuals and 19 coin-
fected and non-cirrhotics individuals were included. The median (quartile 1 –quartile 3) age at
the liver transplant date was 47.3 (43.8–50.2) years, and the median (quartile 1 –quartile 3) age
of controls was 49.2 (45.1–53.6) years, (p = 0.29). The medians of time since the coinfection
date were 22.3 (18.5–25.2) and 21.9 (10.0–27.5) years for liver transplanted and control indi-
viduals, respectively (p = 0.137). The gender distribution were also similar for both populations
(p>0.400).
Study 1. Genetic factors associated with cirrhosis
In the study population 1, cirrhosis was diagnosed in 81 (24.4%) individuals. The genotypic
distributions of SAMM50 rs738491, LPPR4 rs12743824 and PNPLA3 rs738409 polymorphisms
in cirrhotic and non-cirrhotic individuals are displayed in Table 2. All of them were in accor-
dance with the Hardy-Weinberg equilibrium (p>0.400 in all cases).
Only the PNPLA3 rs738409 genetic marker was associated with cirrhosis. Thus, we observed
that among 152 individuals carrying the G allele (GG and GC genotypes), 45 (29.6%) showed
this condition, whereas the proportion of cirrhotic subjects among those bearing the CC geno-
type was 20.0% (36 out of 180 individuals) (p = 0.042; OR = 1.683; 95%CI = 1.016–2.786).
In the univariate analysis, other factors associated with cirrhosis were older age, lower total
cholesterol levels and alcohol intake (Table 2). Factors that remained independently related to
PNPLA3 and Cirrhosis in HIV/HCV Coinfection
PLOS ONE | DOI:10.1371/journal.pone.0168265 December 14, 2016 4 / 13
cirrhosis in the multivariate analysis were the presence of the PNPLA3 rs738409 G allele, older
age, lower HCV viral load and total cholesterol levels (Table 2).
Study 2. Factors associated with significant liver stiffness progression
Among the 171 patients with paired LS determinations, 37 (21.6%) were classified as individu-
als with significant LSP. No differences were observed in the median time between LS determi-
nations in patients with and without significant LSP (median [quartile 1 –quartile 3]: 2.56
[1.27–5.39] years versus 2.17 [1.29–4.30] years, respectively; p = 0.561).
Table 1. Main characteristics of the study population 1 and the subpopulation where liver stiffness progression was evaluated.
Variables Study population 1 (n = 332) Subpopulation with two LS determinations * (n = 171)
Male gender, n (%) 287 (86.4) 145 (84.8)
Agea, years 47 (43–50) 45 (41–49)
Alcohol intake 50g/day, n (%) 59 (18.4) b 38 (22.2) e
BMIa, Kg/m2 23.5 (21.4–26.2) c 22.8 (20.8–25.8) f
Fasting plasma glucosea, mg/dL 94 (87–106) 94 (86.75–103)
Total plasma cholesterola, mg/dL 166 (142.3–188.5) 167 (143.5–201.3)
Plasma LDL cholesterola, mg/dL 91 (71–112) 93 (67–115)
Plasma HDL cholesterola, mg/dL 43 (34–53) 40.5 (31–53)
Plasma trygliceridesa, mg/dL 135.5 (93.3–173.8) 144 (105.3–190.8)
ALTa, IU/L 50 (33–79) 52 (37–80)
ASTa, IU/L 46 (31–69) 47 (34–72.5)
GGTa, IU/L 94 (55–174) 95 (53–175)
CD4a cell/microL 479 (311–710) 469 (301–685)
Serum HIV-RNA <50 Copies/mL, n (%) 261 (78.6) 117 (70.1) g
CDC stage C, n (%) 101 (30.7) d 33 (29.2) h
Current ART, n (%) 319 (96.1) 161 (94.2)
HCV Genotype, n (%)
1 210 (63.3) 106 (62.0)
2 1 (0.3) 0 (0.0)
3 52 (15.7) 27 (15.8)
4 61 (18.4) 30 (17.5)
Unknown 8 (2.4) 8 (4.7)
HCV viral loada, log IU/mL 6.2 (5.6–6.6) ND
Liver stiffnessa, kPa 8.6 (5.8–13.8) 8.1 (5.8–13.2)
CAPa, dB/m 229.5 (201.2–260.8) ND
LS, liver stiffness; BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; GGT, gamma-glutamyl transferase CDC, Centers for Disease Control and Prevention; ART, antiretroviral therapy; HCV, hepatitis C
virus; CAP, controlled attenuation parameter; ND, not determined.
*values obtained at the date of the first Liver stiffness determination
a Median (quartil 1 –quartil 3).
Available in
b320,
c309,
d329,
e157,
f80,
g167,
h113 patients.
doi:10.1371/journal.pone.0168265.t001
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The genotypic distributions of the three SNPs analyzed are displayed in Table 3.
No association was found between SAMM50 rs738491 or LPPR4 rs12743824 and significant
LSP. A higher proportion of PNPLA3 rs738409 G allele carriers was observed in individuals
with significant LSP. Thus, among 69 individuals carrying the G allele, 21 (30.4%) showed sig-
nificant LSP, whereas for those bearing the CC genotype the frequency of significant LSP was
15.7% (16 out of 102 individuals) (p = 0.022; OR = 2.35; 95% CI = 1.12–4.92). Accordingly,
LSPR was significantly higher in GG/GC carriers than that observed for CC carriers (median
[quartile 1 –quartile 3]: 0.27 [-0.25–2.07] kPa/year versus 0.00 [-0.78–0.81] kPa/year, respec-
tively; p = 0.014) (Fig 1).
Table 3 shows other factors associated with significant LSP in the univariate analysis. In the
multivariate analysis, only the presence of the PNPLA3 rs738409 G allele and high alcohol
intake remained as independent factors associated with this outcome (Table 3). When the
same analysis was carried out excluding individuals with cirrhosis at baseline the presence of
Table 2. Univariate and multivariate analysis of factors associated with cirrhosis (Study 1).
Variables Univariate Multivariate
Non-cirrhotics (n = 251) Cirrhotics (n = 81) p-value AOR (95%CI) Adjusted p-value
Male gender, n (%) 214 (85.3) 73 (90.1) 0.266 1.47 (0.64–3.41) 0.369
Agea, years 46 (43–50) 48 (45–51) 0.006 1.12 (1.06–1.19) <0.001
Alcohol intake 50g/day, n (%) 38 (15.8) 21 (26.6) 0.031 1.56 (0.78–3.13) 0.208
BMIa, Kg/m2 23.7 (21.5–26.2) 23.2 (21.4–26.2) 0.852 NI NI
Fasting plasma glucosea, mg/dL 94 (87–105) 96 (86–112) 0.218 NI NI
Plasma total cholesterola, mg/dL 171 (150–190) 150 (121–175) <0.001 0.981 (0.97–0.98) <0.001
Plasma Triglyceridesa, mg/dL 134 (93–176) 136 (92–160) 0.827 NI NI
HIV-RNA <50 Copies/mL, n (%) 200 (79.7) 61 (75.3) 0.404 NI NI
CDC stage C, n (%) 76 (30.5) 25 (31.2) 0.902 NI NI
Current ART, n (%) 243 (96.8) 76 (93.8) 0.228 NI NI
Significant steatosis, n (%) 124 (39.1) 44 (45.4) 0.273 NI NI
HCV Genotype 3, n (%) 42 (17.1) 10 (12.7) 0.352 NI NI
HCV viral load, Log (IU/mL) a 6.2 (5.6–6.7) 6.0 (5.4–6.5) 0.051 0.67 (0.46–0.97) 0.035
rs738491 (SAMM50) 0.527b NI NI
CC, n (%) 129 (51.4) 36 (44.4)
CT, n (%) 98 (39.0) 35 (43.2)
TT, n (%) 24 (9.6) 10 (12.3)
rs12743824 (LPPR4) 0.513b NI NI
AA, n (%) 54 (21.5) 13 (16.0)
AC, n (%) 117 (46.6) 39 (48.1)
CC, n (%) 80 (31.9) 29 (35.8)
rs738409 (PNPLA3) 0.042b 1.98 (1.12–3.50) 0.018
CC, n (%) 144 (57.4) 36 (44.4)
GC, n (%) 90 (35.9) 35 (43.2)
GG, n (%) 17 (6.8) 10 (12.3)
BMI, body mass index; CDC, Centers for Disease Control and Prevention; ART, antiretroviral therapy; PI, Protease Inhibitor; HCV, hepatitis C virus;
SAMM50, sorting and assembly machinery component 50 homolog; LPPR4, lipid phosphate phosphatase-related protein type 4; PNPLA3, patatin-like
phospholipase domain containing 3; CI, confidence interval; AOR, adjusted odds ratio; NI, not included in the model.
a Median (interquartile range).
b Pearson Chi-square (TT vs. CC+CT for rs738491, AA+AC vs. CC for rs12743824, GG+GC vs. CC for r rs738409).
doi:10.1371/journal.pone.0168265.t002
PNPLA3 and Cirrhosis in HIV/HCV Coinfection
PLOS ONE | DOI:10.1371/journal.pone.0168265 December 14, 2016 6 / 13
the PNPLA3 rs738409 G showed a trend to association with significant LSP (adjusted p-
value = 0.053; adjusted odds ratio = 2.73; 95% CI = 0.98–7.56).
Study 3. Role of rs738409 in patients with end stage of liver disease
We analyzed the PNPLA3 rs738409 genotypic distribution in 28 HIV/HCV-coinfected indi-
viduals who underwent a liver transplant because of end-stage liver disease, as well as, in 19
coinfected and non-cirrhotics controls (study population 2). In the end-stage liver disease
group, 8 (28.6%) individuals were CC, 16 (57.1%) were GC and 4 (14.3%) were GG. The corre-
sponding figures for the control group were 11 (57.9%) CC, 7 (36.8%) GC and 1 (5.3%) GG.
Table 3. Associations with significant liver stiffness progression (Study 2).
Variables Univariate Multivariate
Non-significant LSP (n = 134) Significant LSP (n = 37) p-value AOR (95%CI) Adjusted p-value
Male gender, n (%) 112 (83.6) 33 (89.2) 0.605 1.41 (0.392–5.04) 0.599
Agea, years 44 (40–49) 46 (42–49) 0.652 1.04 (0.96–1.12) 0.307
Alcohol intake 50g/day, n (%) 26 (20.8) 12 (37.5) 0.049 2.63 (1.04–6.67) 0.041
BMIa, Kg/m2 23.1 (20.8–26.1) 22.1 (20.5–23.8) 0.827 NI NI
Plasma glucosea, mg/dL 94 (87–103) 95 (85–104) 0.911 NI NI
Plasma total cholesterola, mg/dl 171 (146–202.5) 160 (138.5–185.5) 0.533 NI NI
Plasma HDL cholesterola, mg/dl 40 (31–53) 41 (31–53) 0.781 NI NI
Plasma trygliceridesa, mg/dl 145 (108–188) 143 (88–197) 0.944 NI NI
ALTa, IU/L 49 (37–78) 61 (36–119) 0.094 0.99 (0.98–1.01) 0.849
ASTa, IU/L 44 (33.5–67) 58 (41–111.5) 0.015 1.01 (0.99–1.01) 0.331
GGTa, IU/L 91 (52–160) 138 (57.5–222) 0.048 1.00 (0.99–1.01) 0.051
HIV-RNA <50 Copies/mL, n (%) 94 (71.2) 23 (65.7) 0.528 NI NI
CDC stage C, n (%) 26 (29.9) 7 (26.9) 0.771 NI NI
Current ART, n (%) 128 (95.5) 33 (89.2) 0.226 NI NI
HCV Genotype 3, n (%) 21 (16.5) 6 (16.7) 0.985 NI NI
Time between LS determinationsa, years 2.2 (1.3–4.3) 2.5 (1.3–5.4) 0.561 1.08 (0.88–1.33) 0.844
Cirrhosis at baseline, n (%) 28 (20.9) 10 (27.0) 0.427 NI NI
rs738491 (SAMM50) 0.577b NI NI
CC, n (%) 76 (56.7) 18 (48.6)
CT, n (%) 41 (30.6) 13 (35.1)
TT, n (%) 17 (12.7) 6 (16.2)
rs12743824 (LPPR4) 0.569b NI NI
AA, n (%) 24 (17.9) 7 (18.9)
AC, n (%) 66 (49.3) 16 (43.2)
CC, n (%) 44 (32.8) 14 (37.8)
rs738409 (PNPLA3) 0.022b 2.89 (1.23–6.83) 0.015
CC, n (%) 86 (64.2) 16 (43.2)
GC, n (%) 38 (28.4) 18 (48.2)
GG, n (%) 10 (7.5) 3 (8.1)
LSP, Liver stiffness progression; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl
transpeptidase; CDC, Centers for Disease Control and Prevention; ART, antiretroviral therapy; HCV, hepatitis C virus; SAMM50, sorting and assembly
machinery component 50 homolog; LPPR4, lipid phosphate phosphatase-related protein type 4; PNPLA3, patatin-like phospholipase domain containing 3;
CI, confidence interval; AOR, adjusted odds ratio; NI, not included in the model.
a Median (interquartile range).
b Pearson Chi-square (TT vs. CC+CT for rs738491, AA+AC vs. CC for rs12743824, GG+GC vs. CC for r rs738409).
doi:10.1371/journal.pone.0168265.t003
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The genotypic distribution and the allelic frequencies of these polymorphisms observed in the
control group were in accordance with those published for European Caucasian populations
(p>0.700). The proportion of GG/GC carriers was higher in HIV/HCV-coinfected patients
with end-stage liver disease than in control individuals (p = 0.044, OR = 3.43; CI = 1.01–
11.70).
Discussion
The results obtained in this study support that the FLD-related PNPLA3 rs738409 genetic vari-
ant is associated with liver disease progression in HIV/HCV-coinfected patients. On the con-
trary, others SNPs associated with FLD in the HIV-infected population such as SAMM50
rs738491 and LPPR4 rs12743824 do not seem to have a relevant role on liver disease evolution
in these patients.
Even though PNPLA3 rs738409 has been widely studied in different chronic liver diseases,
the influence of this polymorphism on liver fibrosis progression in HIV/HCV-coinfected
patients has not been consistently established [8–11]. Thus, Mandorfer et al, [11] identified an
univariate association between PNPLA3 rs738409 G allele and faster fibrosis progression rate
in a preliminary study carried out in a small sample of HIV/HCV-coinfected individuals.
However, they did not detected any relationship between PNPLA3 rs738409 and stage of
Fig 1. Liver stiffness progression rate according to PNPLA3 rs738409 genotype.
doi:10.1371/journal.pone.0168265.g001
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fibrosis in a recent study performed in 177 HIV/HCV-coinfected patients [9]. Similarly, the
authors of a recent work analyzed 168 coinfected patients and reported no association between
this variant and advanced liver fibrosis [10]. By contrast, in another study performed in a
sample of 215 HIV/HCV-coinfected individuals, a significant association between PNPLA3
rs738409 G allele and advanced fibrosis was found [8]. Nevertheless, in the latter study, the
association of the PNPLA3 genetic variation with fibrosis progression did not reach the level of
statistical significance. Since the development of advanced fibrosis in HCV-infected individu-
als is influenced by the duration of HCV infection, and, consequently, by age [17], the contra-
dictory results about the association between PNPLA3 rs738409 G allele and fibrosis could be
due to the cross-sectional design of some of these studies. The size of the sample included is an
additional issue. Thus, association studies with advanced liver fibrosis as end-point need large
populations and/or validations in separate populations. These requirements were not fulfilled
in the above-stated studies. A more comprehensive approach to this problem is to test the
influence of PNPLA3 rs738409 G allele on the progression of liver disease. Two studies ana-
lyzed this outcome and reported a trend toward the association [8] or an univariate association
[11]. Our study, which was carried out in a larger sample, identified the presence of PNPLA3
rs738409 G allele as an independent risk factor for cirrhosis in HIV/HCV-coinfected patients.
Moreover, as a validation of this finding, we detected a higher frequency of PNPLA3 rs738409
G allele carriers in a group of HIV-infected individuals who had reached end-stage of liver dis-
ease due to HCV infection. This association was also confirmed by proving a relationship
between this polymorphism and significant LSP. Taken together, our results clearly support
the implication of PNPLA3 rs738409 on fibrosis progression and, ultimately, the development
of cirrhosis in HIV/HCV coinfection. These findings are also in agreement with those
obtained in the HCV monoinfection setting where PNPLA3 rs738409 has been associated with
both, cirrhosis [18, 19] and fibrosis progression [20–22].
We previously reported a lack of association between the PNPLA3 rs738409 variant and
FLD in HIV/HCV-coinfected individuals [14]. Although Signelli et al. found a relation of this
SNP with steatosis in a small population [10], our finding has been replicated by others [8, 9].
This was a relatively surprising result since this genetic variant has been extensively related to
non-alcoholic FLD in general population [23–25] and in HCV-monoinfected patients [18, 20,
26, 27]. The relation of this genetic variant to cirrhosis without a clear association with FLD in
the HIV/HCV-coinfected population could be pointing out to the existence of other factors
that modulate the effect of this variant on the liver [22]. More studies are warranted to eluci-
date this issue. By contrast, the other SNPs evaluated here, linked to SAMM50 and LPPR4
genes, which were previously associated with FLD in the HIV-infected population [14], have
not shown any association with cirrhosis or significant LSP in our study. Taking into account
the sample size analyzed, the case-control ratio and the minor allele frequency of those genetic
markers in our population, our study had a 75% and 80% power to detect OR = 2 for the study
of association of SAMM50 rs738491 and LPPR4 rs12743824 polymorphisms with cirrhosis,
respectively. Consequently, the absence of association with cirrhosis is probably not due to the
lack of statistical power. Therefore, our results suggest that these genetic markers do not have a
prevalent role on fibrosis progression.
During the last years, many studies have focused on unraveling the pathophysiological
mechanisms of PNPLA3 effects. However they are still unclear [28]. PNPLA3 is a lipase highly
expressed in human liver and adipose tissue. Alterations produced by PNPLA3 rs738409 poly-
morphism yield changes in the enzyme catalytic binding site leading to the cellular triglyceride
accumulation [29]. This mechanism could explain the etiology of FLD and its relation to
PNPLA3 rs738409 polymorphism. However, this hypothesis have not been validated in any in
vivo experiment performed so far [28]. In addition, PNPLA3 also seems to have a key role as a
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liver metabolic modulator, and PNPLA3 rs738409 polymorphism could produce a shift to
anaerobic metabolism and mitochondrial dysfunction in hepatocytes [30]. This could explain
its contribution to other liver diseases, as HCV-related liver disease. However, more studies
are necessary to test this hypothesis.
Our study has some limitations. First, the sample sizes of study population 2 and the sub-
population where LSP was analyzed, were relatively small. In spite of this, the effect of PNPLA3
rs738409 was in the same direction in all cases. Second, the longitudinal analysis carried out in
that subpopulation was retrospective. Therefore, the quality and quantity of clinical data could
have been limited to their availability and, selection bias cannot be excluded. Nevertheless, we
did not observe considerable differences between the study population 1 and the subpopula-
tion where LSP was analyzed (Table 1). Third, we included cirrhotic patients at the date of the
first LS determination (baseline) to assess factors associated with significant LSP. Generally,
these patients are excluded when fibrosis progression is evaluated in liver biopsy studies. This
was due to the calculation of fibrosis progression using fibrosis staging classifications, where
individuals in the last stage of fibrosis are not susceptible to progress anymore. However, LSP
also occurs in cirrhosis stage (>14.5 kPa) and, it has been reported that patients with LS values
over specific LS cut-off values, such as 21 kPa or 40 kPa, have a poorer prognosis [31, 32]. In
addition, increases in LS in patients with cirrhosis have been proven to be associated with liver
decompensation [33, 34]. Thus, we believe that the inclusion of these individuals in the study
of LSP allows a comprehensive analysis of this trait. Of note, when these individuals were not
included, the presence of the PNPLA3 rs738409 G allele trended to be associated with signifi-
cant LSP. Fourth, since we used significant LSP as the main variable instead of LSPR, the asso-
ciations found with significant LSP might be confounded by the length of time between LS
determinations. For that reason, multivariate analysis performed in the subpopulation where
LSP was studied was adjusted by this variable. Moreover, it is important to note that LSPR was
higher in those patients bearing the PNPLA3 rs738409 G allele (Fig 1).
In conclusion, our results, in combination with previous evidence, confirm a role of
PNPLA3 rs738409 in fibrosis progression in HIV/HCV co-infection. Because of the effect of
this polymorphism on LSP (Table 3), this genetic marker should be taken into account,
together with other risk factors, for identifying coinfected patients at high likelihood of devel-
oping advanced fibrosis. Hence, it could be useful for the prioritization of those patients who
should receive anti-HCV treatment with direct-acting antivirals, mainly in those countries
where the use of these antivirals is restricted.
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